Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04412668
Recruitment Status : Completed
First Posted : June 2, 2020
Last Update Posted : January 29, 2021
Information provided by (Responsible Party):
aTyr Pharma, Inc.

Brief Summary:
A Phase 2 study to evaluate the safety and preliminary efficacy of ATYR1923, compared to placebo, in hospitalized patients with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation

Condition or disease Intervention/treatment Phase
SARS-CoV-2 (COVID-19) Severe Pneumonia Drug: ATYR1923 1 mg/kg Drug: ATYR1923 3 mg/kg Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients will be randomized 1:1:1 to a single IV dose of ATYR1923 1 mg/kg, ATYR1923 3 mg/kg, or placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The Investigator, Sponsor, and patient will be blinded to treatment assignment; study center pharmacy personnel will be unblinded.
Primary Purpose: Treatment
Official Title: A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
Actual Study Start Date : June 12, 2020
Actual Primary Completion Date : December 21, 2020
Actual Study Completion Date : December 21, 2020

Arm Intervention/treatment
Experimental: ATYR1923 1 mg/kg
Single dose of ATYR1923 1 mg/kg
Drug: ATYR1923 1 mg/kg
1 mg/kg of ATYR1923 administered intravenously

Experimental: ATYR1923 3 mg/kg
Single dose of ATYR1923 3 mg/kg
Drug: ATYR1923 3 mg/kg
3 mg/kg of ATYR1923 administered intravenously

Placebo Comparator: Placebo
Single dose of Placebo
Drug: Placebo
Placebo administered intravenously

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline through Day 60 ]

Secondary Outcome Measures :
  1. Time to hospital discharge [ Time Frame: Baseline through Day 60 ]
  2. Time to recovery (World Health Organization [WHO] Ordinal Scale score ≤3) [ Time Frame: Baseline through Day 60 ]
  3. Proportion of patients achieving recovery by Day 14 and Day 28 [ Time Frame: Baseline through Day 14 and Day 28 ]
  4. Duration of supplemental oxygen (O2) requirement [ Time Frame: Baseline through Day 60 ]
  5. Number of days with fever (temperature >100.4ºF [38.0ºC]) [ Time Frame: Baseline through Day 14 or discharge ]
  6. Change from baseline in World Health Organization (WHO) Ordinal Scale score on Days 5, 7, 14, 28, and 60 [ Time Frame: Baseline through Day 60 ]
  7. Time to improvement from inpatient hospital admission based on at least a 1 point reduction in WHO Ordinal Scale score [ Time Frame: Baseline through Day 60 ]
  8. All-cause mortality at Days 14, 28, and 60 [ Time Frame: Baseline through Day 60 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmation of SARS-CoV2 infection by PCR.
  • Severe pneumonia related to SARS-CoV2 infection, defined as fever or suspected respiratory infection with radiographic abnormalities suggestive of viral pneumonia, plus at least one of the following:

    • Respiratory rate >30 breaths/min; or
    • Severe respiratory distress, as determined by the Investigator; or;
    • Oxygen saturation (SpO2) ≤93% on room air.

Exclusion Criteria:

  • Patient is intubated/mechanically ventilated.
  • In the opinion of the Investigator, patient's progression to death is imminent.
  • Treatment with immunosuppressant/immunotherapy drugs, including but not limited to IL-6 inhibitors, TNF-α inhibitors, anti-IL-1 agents and janus kinase inhibitors within 5 half-lives or 30 days prior to Day 1.
  • Use of chronic (>30 days) oral corticosteroids for a non COVID 19-related condition in a dose higher than prednisone 10 mg or equivalent per day.
  • Weight >165 kg or <40 kg.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04412668

Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, District of Columbia
aTyr Investigative Site
Washington, District of Columbia, United States, 20010
United States, Florida
University of Miami
Miami, Florida, United States, 33125
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Maryland
Anne Arundel Medical Center
Annapolis, Maryland, United States, 21401
United States, New Jersey
aTyr Investigative Site
Vineland, New Jersey, United States, 08360
United States, Ohio
aTyr Investigative Site
Toledo, Ohio, United States, 43614
United States, Virginia
Inova Fairfax Medical Campus
Falls Church, Virginia, United States, 22042
Puerto Rico
Alliance Medical Service, Cardio Pulmonary Research
Guaynabo, Puerto Rico, 00968
Manati Medical Center
Manatí, Puerto Rico, 00674
Sponsors and Collaborators
aTyr Pharma, Inc.
Layout table for investigator information
Study Director: Gennyne Walker aTyr Pharma, Inc.
Layout table for additonal information
Responsible Party: aTyr Pharma, Inc. Identifier: NCT04412668    
Other Study ID Numbers: ATYR1923-C-003
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: January 29, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by aTyr Pharma, Inc.:
acute respiratory distress syndrome
SARS-CoV-2 Infection
Severe Pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases